Research progress of immune regulation mediated by PD-1/PD-L1 immune whistle in rheumatoid arthritis
LIU Lu XU Yuansheng HUANG Weiqian CHEN Jianmin LIU Guoyin▲
Department of Orthopaedics, Qinhuai District Medical Area of Eastern Theater Command of Chinese People’s Liberation Army, Jiangsu Province, Nanjing 210002, China
Abstract：programmed death receptor-1 (PD-1) / programmed death ligand-1(PD-L1) immune whistle is a negative immunomodulatory signal, which is activated or suppressed according to the immune status. Targeted drugs based on PD-1 and PD-L1 have been used in tumor immunotherapy at home and abroad and achieved remarkable effects. However, the relevant therapeutic effects of this target in rheumatoid arthritis (RA) are still divergent. Based on the latest research progress, the pathogenesis of RA induced by immune regulation mediated by PD-1/PD-L1 immune whistle is summarized as follows: With the progression of RA and the repeated changes between active and quiescent phases, persistent and/or high expression of PD-1/PD-L1→impaired or depleted immune cell function→disorder of immune tolerance and immune balance→enhanced immune response→promoted or aggravated the progression of RA. This article reviews the role of immune regulation mediated by PD-1/PD-L1 immune whistle in RA.
[1] Weyand CM，Goronzy JJ. The immunology of rheumatoid arthritis [J]. Nat Immunol，2021，22（1）：10-18.
[2] Akiyama M，Kaneko Y. Pathogenesis，clinical features，and treatment strategy for rheumatoid arthritis-associated interstitial lung disease [J]. Autoimmun Rev，2022，21（5）：103056.
[3] Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer [J]. J Exp Clin Cancer Res，2019，38（1）：255.
[4] Hayashi H，Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer [J]. Int J Clin Oncol，2020，25（5）：818-830.
[5] Xia L，Liu Y，Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer： Current Status and Future Directions [J]. Oncologist，2019，24（Suppl 1）：S31- S41.
[6] Luchini C，Bibeau F，Ligtenberg M，et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer，and its relationship with PD-1/PD-L1 expression and tumour mutational burden： a systematic review-based approach [J]. Ann Oncol，2019，30（8）：1232- 1243.
[7] Andrews LP，Yano H，Vignali D. Inhibitory receptors and ligands beyond PD-1，PD-L1 and CTLA-4： breakthroughs or backups [J]. Nat Immunol，2019，20（11）：1425-1434.
[8] Schonrich G，Raftery MJ. The PD-1/PD-L1 Axis and Virus Infections：A Delicate Balance [J]. Front Cell Infect Microbiol，2019，9：207.
[9] D’Alterio C，Buoncervello M，Ierano C，et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1 [J]. J Exp Clin Cancer Res，2019，38（1）：432.
[10] Perez-Ruiz E，Minute L，Otano I，et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy [J]. Nature，2019，569（7756）：428-432.
[11] Kamada T，Togashi Y，Tay C，et al. PD-1（+） regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer [J]. Proc Natl Acad Sci U S A，2019，116（20）：9999-10008.
[12] Zajac AJ，Blattman JN，Murali-Krishna K，et al. Viral immune evasion due to persistence of activated T cells without effector function [J]. J Exp Med，1998，188（12）：2205- 2213.
[13] Hoffmann M，Pantazis N，Martin GE，et al. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection [J]. PLoS Pathog，2016，12（7）：e1005661.
[14] Dirks J，Egli A，Sester U，et al. Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells [J]. Transpl Infect Dis，2013，15（1）：79-89.
[15] Ye B，Liu X，Li X，et al. T-cell exhaustion in chronic hepatitis B infection： current knowledge and clinical significance [J]. Cell Death Dis，2015，6：e1694.
[16] Attanasio J，Wherry EJ. Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease [J]. Immunity，2016，44（5）：1052-1068.
[17] Wang Q，Bardhan K，Boussiotis VA，et al. The PD-1 Interactome [J]. Adv Biol（Weinh），2021，5（9）：e2100758.
[18] Singh A，Mohan A，Dey AB，et al. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis [J]. J Infect Dis，2013， 208（4）：603-615.
[19] Singh A，Dey AB，Mohan A，et al. Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis [J]. Tuberculosis （Edinb），2014，94（3）：197-206.
[20] Singh A，Prasad S. The Immune Checkpoint Protein Programmed Death 1 During HIV Infection in Children： Clinical Relevance and Beyond [J]. J Infect Dis，2019，219（9）：1353-1355.
[21] Burn E，Edwards CJ，Murray DW，et al. The effect of rheumatoid arthritis on patient-reported outcomes following knee and hip replacement：evidence from routinely collected data [J]. Rheumatology （Oxford），2019，58（6）：1016-1024.
[22] Raptopoulou AP，Bertsias G，Makrygiannakis D，et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis [J]. Arthritis Rheum，2010，62（7）：1870-1880.
[23] Liu C，Jiang J，Gao L，et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways [J]. Arthritis Res Ther，2015，17：340.
[24] Frigola X，Inman BA，Krco CJ，et al. Soluble B7-H1：differences in production between dendritic cells and T cells [J]. Immunol Lett，2012，142（1/2）：78-82.
[25] Wang G，Hu P，Yang J，et al. The effects of PDL-Ig on collagen-induced arthritis [J]. Rheumatol Int，2011，31（4）：513-519.
[26] Menzies AM，Johnson DB，Ramanujam S，et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab [J]. Ann Oncol，2017，28（2）：368-376.
[27] Cappelli LC，Gutierrez AK，Baer AN，et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab [J]. Ann Rheum Dis，2017，76（1）：43-50.
京公网安备 11010502046598号